Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermira Inc.

www.dermira.com

Latest From Dermira Inc.

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Commercial Capsules: Autoimmune Positioning; Sanofi In China; Migraine Race; BMS Deal; Clinical Advances

AbbVie outlines how it will stay top dog in autoimmune therapy; Dermira licenses lebrikizumab, threatening pressure on Sanofi/Regeneron's Dupixent; Sanofi has driven up vaccine sales in China after responding to new government distribution rules; Lilly plans a migraine filing; FibroGen, Myokardia and Hansa Medical advance in the clinic and Bristol-Myers shells out up to $2.3bn to turn cold tumors hot. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.

Clinical Trials Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Skintelligence Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dermira Inc.
  • Senior Management
  • Thomas G Wiggans, CEO
    Andrew Guggenhime , COO & CFO
    Eugene A Bauer, MD, CMO
    Chris Griffith, VP, Corp. Dev. & Strategy
    Christine Conroy , SVP, Reg. Affairs
    Hans Hofland, PhD, VP, Research & Nonclinical Dev.
    Lori Lyons-Williams, Chief Commercial Officer
  • Contact Info
  • Dermira Inc.
    Phone: (650) 421-7200
    275 Middlefield Rd.
    Ste. 150
    Menlo Park, CA 94025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register